홈 > 시장보고서 > 의약품 > 바이오의약품

시장보고서

상품코드

1372502

항체약물접합체 시장 규모 및 예측, 세계 및 지역별 점유율, 동향, 성장 기회 분석 리포트 대상 범위 : 기술별, 용도별, 유통 채널별, 지역별

Antibody Drug Conjugates Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Technology, Application, Distribution Channel, and Geography

발행일: 2023년 10월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 178 Pages | 배송안내 : 즉시배송

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항체약물접합체 시장은 2022년에는 77억 9,300만 달러에 달하며, 2030년에는 296억 달러에 달할 것으로 예상되며, 2022-2030년의 CAGR은 18.2%로 추정됩니다.

항체약물접합체 시장 개척은, 항체약물접합체를 개발하기 위한 전략적 파트너십의 신흥 시장의 확대, 암환자의 증가, 항체약물접합체에 대한 FDA 승인의 증가 등에 기인하고 있습니다. 그러나 항체약물접합체의 개발과 상업화에 드는 비용이 높은 것이 시장 성장의 방해가 되고 있습니다.

항체약물접합체 개발을 위한 전략적 파트너십의 확대

항체약물접합체는 암 치료에서 세계에서 큰 주목을 받고 있으며, 2000년 미국 식품의약국(FDA)이 화이자의 첫 번째 항체약물접합체인 마일로탁을 승인한 이후 COVID-19 팬데믹에도 불구하고 제약사 리더들의 전략적 결정이 크게 증가하고 있습니다. 2020년에는 다양한 제약회사들이 항체약물접합체 개발을 위한 제휴를 맺었습니다. 예를 들어 2020년 7월 아스트라제네카와 다이이찌산쿄는 DS-1602를 개발 및 상용화하기 위해 협력했는데, DS-1602는 다이이찌산쿄가 독자적으로 개발한 융모세포 표면 항원2(TROP2) 지향성 항체약물접합체로서 여러 종양 유형을 치료합니다.

이미 2022년 12월, 머크(Merck &Co., Inc., MSD)와 켈룬바이오텍(사천 쾰른제약의 자회사)은 암 치료를 위한 7개의 전임상 항체약물접합체 개발을 위해 협력하기로 했습니다. 이번 계약에 따라 MSD는 켈룬바이오텍으로부터 다수의 전임상 항체약물접합체 치료제의 연구개발, 제조 및 상업화에 대한 세계 독점적 라이선스를 부여받았습니다. 또한 MSD는 항체약물접합체 후보물질에 대한 추가 라이선스를 획득할 수 있는 독점적 옵션을 보유하고 있습니다. 한편, 중국 본토, 홍콩 및 마카오의 경우, 쾰른 바이오텍은 특정 라이선스 및 옵션 항체약물접합체의 연구, 개발, 제조 및 상업화에 대한 권리를 보유하고 있습니다.

또한 2023년 4월, BioNTech SE와 Duality Biologics(Suzhou) Co. Ltd.는 암과 자가면역질환을 치료하는 차세대 항체약물접합체를 개발하기 위한 전략적 파트너십 계약을 체결했습니다. 이번 파트너십 계약을 통해 BioNTech SE는 DualityBio의 선도 후보물질인 DB-1303(인간 상피세포 성장인자 수용체 2(HER2)에 대한 토포이소머라제-1 억제제 기반 항체약물접합체 DB-1303을 확보할 수 있게 되었습니다. 대부분의 암종에서 과발현되는 공통 표적으로 암세포의 공격적인 성장과 확산에 기여합니다. 둘째, BioNTech SE는 또 다른 토포이소머라제-1 억제제 기반 항체약물접합체 후보물질인 DB-1311에 접근할 수 있게 됩니다. 양사는 혁신적인 치료법의 세계 혁신과 상용화를 목표로 하고 있습니다.

항체약물접합체 시장 : 부문별 개요

항체약물접합체 시장은 기술, 애플리케이션, 유통 채널 및 지역별로 분류됩니다. 기술에 따라 항체약물접합체 시장은 절단 가능 링커와 비 절단 가능 링커로 구분되며, 2022년에는 절단 가능 링커 부문이 더 큰 시장 점유율을 차지하고 비 절단 가능 링커 부문은 2022-2030년간 더 빠른 CAGR을 기록할 것으로 추정됩니다. 개질 가능한 링커는 화학적 트리거 또는 구조적 특성을 이용하여 종양 세포 내에서 세포 독성 페이로드를 방출합니다. 이 기술은 pH 민감성, 글루타티온 민감성, 프로테아제 민감성 메커니즘을 화학적 트리거로 활용합니다. 개질 가능한 링커 기술은 항체약물접합체 개발에 널리 사용되고 있습니다. 2021년 3월에 발표된 논문 '항체약물접합체: Recent advances in linker chemistry'에 따르면 승인된 항체약물접합체의 80% 이상이 개질 가능한 링커 기술을 이용해 만들어졌습니다. 베스폰사(이노투주맙오조가마이신)와 애드세트리스(브렌툭시맙베도틴)는 이 기술을 사용하여 합성된 항체약물접합체의 두 가지 대표적인 예입니다. 이러한 항체약물접합체는 친수성 추적성이 없는 페이로드를 방출한 후에도 혈액 순환에서 비교적 오랜 기간 중 안정적입니다. 또한 절단 가능한 링커는 페이로드를 세포 내로 방출할 수 있습니다.

항체약물접합체 시장은 용도별로 혈액암, 유방암, 난소암, 요로상피암, 기타로 구분되며, 2022년에는 유방암 분야가 가장 큰 시장 점유율을 차지하고 2022-2030년 CAGR이 18.6%로 가장 빠를 것으로 추정됩니다. 항체약물접합체의 사용은 유방암 치료 계획 방법을 크게 변화시켰습니다. 항체약물접합체의 개발은 유방암 치료제의 효능, 정확성 및 안전성을 향상시킬 것으로 예상됩니다. 현재 카도사이라/T-DM1(애드트러스주맙엠탄신), 엔헬츠/T-DXd(트라스투주맙델렉스테칸), 트로델비/SG(사시투주맙고베탄)가 삼중음성유방암(TNBC) 및 전이성 유방암 치료제로 시판되고 있습니다. 2023년 1월에 발표된 Breast Cancer Research Foundation의 데이터에 따르면 17개의 항체약물접합체가 임상시험 중에 있습니다. 이 중 9개는 HER2 지향성 항체약물접합체로 다양한 페이로드의 조합으로 연구되고 있습니다. 나머지 8개의 항체약물접합체는 새로운 항체 표적과 결합하여 연구되고 있습니다.

항체약물접합체 시장 : 지역별 개요

북미가 항체약물접합체 시장에서 가장 큰 점유율을 차지하고 있습니다. 이 지역의 항체약물접합체 시장은 미국, 캐나다, 멕시코로 나뉘어져 있습니다. 이 지역 시장 성장 배경에는 항체약물접합체 연구개발 증가, 제품 승인 증가, 항체약물접합체에 대한 인지도 향상, 업체 간 합병, 제휴 및 파트너십 증가 등이 있습니다. 또한 암 발병률이 크게 증가하고 있는 것도 항체약물접합체 수요를 확대하는 주요 요인 중 하나입니다.

미국, 북미 및 세계 항체 약물 복합제 시장에서 가장 큰 기여를 하고 있습니다. 미국 식품의약국(FDA)은 2021년 1월까지 여러 암 적응증에 대해 Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, Blenrep, Padcev, Blenrep을 승인했습니다. 또한 미국에서는 여러 항체약물접합체가 파이프라인에 있습니다. 항체약물접합체는 첨단 접합 기술, 더 강력한 페이로드, 새로운 항원 표적화, 새로운 링커 등의 전략으로 개발되고 있으며, 2021년 5월에 발표된 FDA 데이터에 따르면 40개 이상의 서로 다른 표적에 대한 77개의 새로운 항체약물접합체에 대해 113개의 임상시험이 연구 중이었습니다. 파이프라인에 있는 항체약물접합체 리스트이 증가함에 따라 국내 항체약물접합체 시장 규모는 향후 확대될 것으로 추정됩니다.

또한 항체약물접합체 시장의 리더들 간의 파트너십 확대는 각 지역에서의 기술 확장 및 시장 성장을 가능하게할 것입니다.2023년 8월, 면역젠과 다케다제약은 면역젠의 항체약물접합체 치료제 '엘라히어(ELAHERE)'의 일본에서의 개발 및 상용화를 위해 제휴했습니다. 이번 제휴 계약에 따라 이뮤노젠은 백금제제 내성 난소암을 적응증으로 하는 '엘라히어'의 FDA 신속승인 획득시 계약금 및 추가금을 받게 됩니다. 또한 다케다약품이 일본내 엘라히어 매출을 통해 일정 약사 및 상업적 마일스톤과 두 자릿수 로열티를 달성할 경우, 다케다약품은 이뮤노젠에 추가금을 지급합니다. 단, 이뮤노젠은 독점적 제조권을 보유하며 일본내 개발 및 상업화를 위해 제품을 공급합니다. 그 대가로 다케다제약은 모든 허가신청을 담당하고 일본내 엘라히어의 독점적 개발 및 판매권을 갖게 됩니다.

미국 식품의약국(FDA), Cancer.Net, 유럽의약품청(EMA), 미국 질병예방통제센터(CDC)의 항체약물접합체 시장 보고서를 작성할 때 참고한 주요 1차 및 2차 정보 중 일부.

주요 시장 촉진요인
- 항체약물접합체 개발을 위한 전략적 파트너십의 확대
- 암환자의 증가
- 항체약물접합체에 대한 FDA 승인의 증가
시장 억제요인
- 항체약물접합체의 개발과 상업화에 드는 고비용
시장 기회
- 항체약물접합체 개발에 대한 투자의 증가
시장 동향
- 항체약물접합체 파이프라인의 증가
영향 분석

제6장 항체약물접합체 시장 : 세계 시장 분석

항체약물접합체 시장 매출(2017-2030년)

제7장 항체약물접합체 시장 : 2030년까지의 매출과 예측 : 기술별

서론
항체약물접합체 시장 2022년 및 2030년 기술별 판매고 점유율(%)
Cleavable Linker
Non-cleavable Linker

제8장 항체약물접합체 시장 : 2030년까지의 매출과 예측 : 용도별

서론
항체약물접합체 시장 2022년 및 2030년 용도별 판매고 점유율(%)
혈액암
유방암
난소암
요로 상피암
기타

제9장 항체약물접합체 시장 : 2030년까지의 매출과 예측 : 유통 채널별

서론
항체약물접합체 시장 2022년 및 2030년 유통 채널별 판매고 점유율(%)
병원 약국
소매 약국
온라인 약국

제10장 항체약물접합체 시장 : 지역별 분석

개요
북미의 항체약물접합체 시장 : 국가별
- 미국
- 캐나다
- 멕시코
개요
유럽의 항체약물접합체 시장 : 국가별
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 기타 유럽
개요
아시아태평양의 항체약물접합체 시장 : 국가별
- 중국
- 일본
- 인도
- 한국
- 호주
- 기타 아시아태평양
개요
중동 및 아프리카의 항체약물접합체 시장 : 국가별
- 사우디아라비아
- 아랍에미리트
- 남아프리카공화국
- 기타 중동 및 아프리카
개요
중남미의 항체약물접합체 시장 : 국가별
- 브라질
- 아르헨티나
- 기타 중남미 국가

제11장 항체약물접합체 시장 - 업계 상황

서론
유기적 성장 전략
무기적 성장 전략
각사의 생산능력

제12장 기업 개요

ADC Therapeutics SA
Pfizer Inc
Hoffmann-La Roche Ltd
ImmunoGen, Inc.
GSK Plc
Gilead Sciences Inc
AstraZeneca Plc
Astellas Pharma Inc
RemeGen Co Ltd
Takeda Pharmaceutical Co Ltd

제13장 부록

KSA 23.11.09

The global antibody drug conjugates market is expected to reach US$ 7.793 billion in 2022 to US$ 29.600 billion by 2030; the market is estimated to record a CAGR of 18.2% from 2022 to 2030.

The market growth of antibody drug conjugates is attributed to growing strategic partnerships to develop antibody drug conjugates, rising incidences of cancer cases, and increasing FDA approvals for ADCs. However, high cost of ADCs development and commercialization is hindering the market growth.

Growing Strategic Partnerships to Develop Antibody Drug Conjugates

Antibody-drug conjugates (ADCs) have received significant attention worldwide for cancer therapy. Since the approval of Mylotarg (Pfizer, Inc.'s first ADC) by the US Food and Drug Administration (FDA) in 2000, there has been substantial growth in strategic decisions by pharmaceutical leaders despite the COVID-19 pandemic. In 2020, various pharmaceutical companies entered into partnerships to develop ADCs. For intance, in July 2020, AstraZeneca and Daiichi Sankyo collaborated to develop and commercialize DS-1062. DS-1602 is Daiichi Sankyo's proprietary trophoblast cell-surface antigen 2 (TROP2)-directed ADC to treat multiple tumor types.

Likewise, in December 2022, Merck & Co., Inc. (MSD) and Kelun-Biotech, a Sichuan Kelun Pharmaceutical Co., Ltd. subsidiary, partnered to develop seven investigational preclinical ADCs to treat cancer. Under the agreement, MSD received a grant for exclusive global licenses from Kelun Biotech to research, develop, manufacture, and commercialize multiple investigational preclinical ADC therapies. In addition, MSD has exclusive options to obtain additional licenses for ADC candidates. Whereas for Mainland China, Hing Kong, and Macau, Kelun-Biotech has retained its rights to research, develop, manufacture, and commercialize certain licensed and option ADCs.

Similarly, in April 2023, BioNTech SE and Duality Biologics (Suzhou) Co. Ltd signed a strategic partnership agreement to develop next-generation ADCs to treat cancer and autoimmune diseases. Under the partnership agreement, BioNTech SE will have access to DualityBio's lead candidate, DB-1303. DB-1303 is a topoisomerase-1 inhibitor-based ADC directed against Human Epidermal Growth Factor Receptor 2 (HER2). HER2 is an overexpressed common target in most cancer types and contributes to cancer cells' aggressive growth and spread. Secondly, BioNTech SE will have access to another topoisomerase-1 inhibitor-based ADC candidate, DB-1311. Companies have aimed to transform and commercialize innovative therapies worldwide.

Antibody Drug Conjugates Market: Segmental Overview

The antibody drug conjugates market is segmented on the basis of technology, application, distribution channel, and geography. Based on technology, the antibody drug conjugates market is bifurcated into cleavable linkers and non-cleavable linkers. In 2022, the cleavable linkers segment held a larger market share, and the non-cleavable linkers segment is estimated to register a faster CAGR during 2022-2030. Cleavable linkers use a chemical trigger or inherent properties of their structure to release the cytotoxic payload in the tumor cells. This technology uses pH sensitivity, glutathione sensitivity, and protease sensitivity mechanisms as chemical triggers. The cleavable linker technology is widely used in developing antibody-drug conjugates (ADCs). According to the article "Antibody-drug conjugates: Recent advances in linker chemistry," published in March 2021, over 80% of the approved ADCs are made using cleavable linker technology. Besponsa (inotuzumab ozogamicin) and Adcetris (brentuximab vedotin) are two notable examples of ADCs synthesized using this technology. These ADCs remain comparatively stable for a long time in blood circulation after releasing hydrophilicity traceless payload. Moreover, cleavable linkers can release the payload intracellularly.

Based on application, the antibody drug conjugates market is segmented into blood cancer, breast cancer, ovarian cancer, urothelial cancer, and others. In 2022, the breast cancer segment held the largest market share, and is estimated to register the fastest CAGR of 18.6% during 2022-2030. The use of ADCs has significantly transformed how breast cancer treatment is planned. The development of ADCs is expected to improve the potency, precision, and safety of breast cancer therapeutics. At present, Kadcyla/T-DM1 (ado-trastuzumab emtansine), Enhertu/T-DXd (trastuzumab deruxtecan), and Trodelvy/SG (sacituzumab govetican) are the commercialized products available in the market to treat triple-negative breast cancer (TNBC) and metastatic breast cancer cases. According to the Breast Cancer Research Foundation data, published in January 2023, 17 ADCs are in clinical trials. 9 out of these are HER2-directed ADCs, which are being studied in different combinations of payloads. The remaining 8 ADCs are being studied in combination with novel antibody targets.

Antibody Drug Conjugates Market: Geographical Overview

North America holds the largest share of the antibody drug conjugates market. The antibody drug conjugates market in this region is split into the US, Canada, and Mexico. The market growth in the region is attributed to increasing research and development for ADCs, rising product approvals, growing awareness about ADCs, and rising number of mergers, collaborations, and partnerships among the operating players. In addition, significantly growing incidences of cancer are among the other leading factors escalating the demand for ADCs.

The US is the largest contributor to the antibody drug conjugates market in North America and the world. The highest numbers of ADCs are approved in the US. By January 2021, the US Food and Drug Administration (FDA) had approved Mylotarg, Lumoxiti, Adcetris, Kadcyla, Enhertu, Trodelvy, Besponsa, Polivy, Padcev, and Blenrep for several cancer indications. In addition, several ADCs are in the pipeline in the US. ADCs have been developed with strategies such as advanced conjugate technologies, more potent payloads, targeting novel antigens, and novel linkers. According to the FDA's data published in May 2021, 113 clinical trials were in studies for 77 novel ADCs that targeted over 40 different targets. The growing list of ADCs in the pipeline is estimated to enhance the antibody drug conjugate market size in the country in the coming future.

In addition, growing partnerships among antibody drug conjugate market leader will expand their technologies in different regions enable market growth. In August 2023, ImmunoGen, Inc. and Takeda Pharmaceutical Company Limited collaborated to develop and commercialize ELAHERE, Immunogen's ADC therapy, in Japan. Under the collaboration agreement, ImmunoGen, Inc. receives upfront and additional payments upon conversion of FDA accelerated approval of ELAHERE to treat platinum-resistant ovarian cancer. If Takeda achieves certain regulatory and commercial milestones and double-digit royalties through the net sales of ELAHERE in Japan, it will pay an additional payment to ImmunoGen, Inc. Nevertheless, Immunogen has retained its exclusive production rights and will supply the product for development and commercialization in Japan. In return, Takeda will be responsible for all regulatory filing and have an exclusive license to develop and commercialize ELAHERE in Japan.

A few of the major primary and secondary sources referred to while preparing the ADC market report on the US Food and Drug Administration (FDA), Cancer.Net, EMA (European Medicines Agency), and Centers for Disease Control and Prevention (CDC).

Reasons to Buy:

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the antibody-drug conjugates.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the global antibody-drug conjugates, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global antibody-drug conjugates trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Antibody Drug Conjugates Market Landscape

4.1 Overview
4.2 PEST Analysis
- 4.2.1 Global PEST Analysis
4.3 List of Vendors
- 4.3.1 List of Vendors in the Value Chain

5. Antibody Drug Conjugates Market - Key Industry Dynamics

5.1 Key Market Drivers:
- 5.1.1 Growing Strategic Partnerships to Develop Antibody Drug Conjugates
- 5.1.2 Rising Incidences of Cancer Cases
- 5.1.3 Increasing FDA Approvals for ADCs
5.2 Market Restraints
- 5.2.1 High Cost of ADCs Development and Commercialization
5.3 Market Opportunities
- 5.3.1 Increasing Investments to Develop ADCs
5.4 Market Trends
- 5.4.1 Escalating Pipeline of ADCs
5.5 Impact Analysis:

6. Antibody Drug Conjugates Market - Global Market Analysis

6.1 Antibody Drug Conjugates Market Revenue (US$ Mn), 2017 - 2030

7. Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Technology

7.1 Overview
7.2 Antibody Drug Conjugates Market Revenue Share, by Technology 2022 & 2030 (%)
7.3 Cleavable Linker
- 7.3.1 Overview
- 7.3.2 Cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Non-cleavable Linker
- 7.4.1 Overview
- 7.4.2 Non-cleavable Linker: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

8. Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Application

8.1 Overview
8.2 Antibody Drug Conjugates Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Blood Cancer
- 8.3.1 Overview
- 8.3.2 Blood Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Breast Cancer
- 8.4.1 Overview
- 8.4.2 Breast Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Ovarian Cancer
- 8.5.1 Overview
- 8.5.2 Ovarian Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Urothelial Cancer
- 8.6.1 Overview
- 8.6.2 Urothelial Cancer: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

9. Antibody Drug Conjugates Market - Revenue and Forecast to 2030 - by Distribution Channel

9.1 Overview
9.2 Antibody Drug Conjugates Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
9.3 Hospital Pharmacies
- 9.3.1 Overview
- 9.3.2 Hospital Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Retail Pharmacies
- 9.4.1 Overview
- 9.4.2 Retail Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Online Pharmacies
- 9.5.1 Overview
- 9.5.2 Online Pharmacies: Antibody Drug Conjugates Market - Revenue and Forecast to 2030 (US$ Million)

10. Antibody Drug Conjugates Market - Regional Analysis

10.1 North America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
- 10.1.1 Overview
- 10.1.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
- 10.1.3 North America: Antibody Drug Conjugates Market, by Technology
- 10.1.4 North America: Antibody Drug Conjugates Market, by Application
- 10.1.5 North America: Antibody Drug Conjugates Market, by Distribution Channel
- 10.1.6 North America: Antibody Drug Conjugates Market, by Country
  - 10.1.6.1 US
    - 10.1.6.1.1 Overview
    - 10.1.6.1.2 US: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.6.1.3 US: Antibody Drug Conjugates Market, by Technology
    - 10.1.6.1.4 US: Antibody Drug Conjugates Market, by Application
    - 10.1.6.1.5 US: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.1.6.2 Canada
    - 10.1.6.2.1 Overview
    - 10.1.6.2.2 Canada: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.6.2.3 Canada: Antibody Drug Conjugates Market, by Technology
    - 10.1.6.2.4 Canada: Antibody Drug Conjugates Market, by Application
    - 10.1.6.2.5 Canada: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.1.6.3 Mexico
    - 10.1.6.3.1 Overview
    - 10.1.6.3.2 Mexico: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.6.3.3 Mexico: Antibody Drug Conjugates Market, by Technology
    - 10.1.6.3.4 Mexico: Antibody Drug Conjugates Market, by Application
    - 10.1.6.3.5 Mexico: Antibody Drug Conjugates Market, by Distribution Channel
10.2 Europe Antibody Drug Conjugates Market, Revenue and Forecast To 2030
- 10.2.1 Overview
- 10.2.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
- 10.2.3 Europe: Antibody Drug Conjugates Market, by Technology
- 10.2.4 Europe: Antibody Drug Conjugates Market, by Application
- 10.2.5 Europe: Antibody Drug Conjugates Market, by Distribution Channel
- 10.2.6 Europe: Antibody Drug Conjugates Market, by Country
  - 10.2.6.1 UK
    - 10.2.6.1.1 Overview
    - 10.2.6.1.2 UK: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.1.3 UK: Antibody Drug Conjugates Market, by Technology
    - 10.2.6.1.4 UK: Antibody Drug Conjugates Market, by Application
    - 10.2.6.1.5 UK: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.2.6.2 Germany
    - 10.2.6.2.1 Overview
    - 10.2.6.2.2 Germany: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.2.3 Germany: Antibody Drug Conjugates Market, by Technology
    - 10.2.6.2.4 Germany: Antibody Drug Conjugates Market, by Application
    - 10.2.6.2.5 Germany: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.2.6.3 France
    - 10.2.6.3.1 Overview
    - 10.2.6.3.2 France: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.3.3 France: Antibody Drug Conjugates Market, by Technology
    - 10.2.6.3.4 France: Antibody Drug Conjugates Market, by Application
    - 10.2.6.3.5 France: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.2.6.4 Italy
    - 10.2.6.4.1 Overview
    - 10.2.6.4.2 Italy: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.4.3 Italy: Antibody Drug Conjugates Market, by Technology
    - 10.2.6.4.4 Italy: Antibody Drug Conjugates Market, by Application
    - 10.2.6.4.5 Italy: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.2.6.5 Spain
    - 10.2.6.5.1 Overview
    - 10.2.6.5.2 Spain: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.5.3 Spain: Antibody Drug Conjugates Market, by Technology
    - 10.2.6.5.4 Spain: Antibody Drug Conjugates Market, by Application
    - 10.2.6.5.5 Spain: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.2.6.6 Rest of Europe
    - 10.2.6.6.1 Overview
    - 10.2.6.6.2 Rest of Europe: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.2.6.6.3 Rest of Europe: Antibody Drug Conjugates Market, by Technology
    - 10.2.6.6.4 Rest of Europe: Antibody Drug Conjugates Market, by Application
    - 10.2.6.6.5 Rest of Europe: Antibody Drug Conjugates Market, by Distribution Channel
10.3 Asia Pacific Antibody Drug Conjugates Market, Revenue and Forecast To 2030
- 10.3.1 Overview
- 10.3.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
- 10.3.3 Asia Pacific: Antibody Drug Conjugates Market, by Technology
- 10.3.4 Asia Pacific: Antibody Drug Conjugates Market, by Application
- 10.3.5 Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel
- 10.3.6 Asia Pacific: Antibody Drug Conjugates Market, by Country
  - 10.3.6.1 China
    - 10.3.6.1.1 Overview
    - 10.3.6.1.2 China: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.1.3 China: Antibody Drug Conjugates Market, by Technology
    - 10.3.6.1.4 China: Antibody Drug Conjugates Market, by Application
    - 10.3.6.1.5 China: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.3.6.2 Japan
    - 10.3.6.2.1 Overview
    - 10.3.6.2.2 Japan: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.2.3 Japan: Antibody Drug Conjugates Market, by Technology
    - 10.3.6.2.4 Japan: Antibody Drug Conjugates Market, by Application
    - 10.3.6.2.5 Japan: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.3.6.3 India
    - 10.3.6.3.1 Overview
    - 10.3.6.3.2 India: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.3.3 India: Antibody Drug Conjugates Market, by Technology
    - 10.3.6.3.4 India: Antibody Drug Conjugates Market, by Application
    - 10.3.6.3.5 India: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.3.6.4 South Korea
    - 10.3.6.4.1 Overview
    - 10.3.6.4.2 South Korea: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.4.3 South Korea: Antibody Drug Conjugates Market, by Technology
    - 10.3.6.4.4 South Korea: Antibody Drug Conjugates Market, by Application
    - 10.3.6.4.5 South Korea: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.3.6.5 Australia
    - 10.3.6.5.1 Overview
    - 10.3.6.5.2 Australia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.5.3 Australia: Antibody Drug Conjugates Market, by Technology
    - 10.3.6.5.4 Australia: Antibody Drug Conjugates Market, by Application
    - 10.3.6.5.5 Australia: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.3.6.6 Rest of Asia Pacific
    - 10.3.6.6.1 Overview
    - 10.3.6.6.2 Rest of Asia Pacific: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.3.6.6.3 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Technology
    - 10.3.6.6.4 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Application
    - 10.3.6.6.5 Rest of Asia Pacific: Antibody Drug Conjugates Market, by Distribution Channel
10.4 Middle East & Africa Antibody Drug Conjugates Market, Revenue and Forecast To 2030
- 10.4.1 Overview
- 10.4.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
- 10.4.3 Middle East & Africa: Antibody Drug Conjugates Market, by Technology
- 10.4.4 Middle East & Africa: Antibody Drug Conjugates Market, by Application
- 10.4.5 Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
- 10.4.6 Middle East & Africa: Antibody Drug Conjugates Market, by Country
  - 10.4.6.1 Saudi Arabia
    - 10.4.6.1.1 Overview
    - 10.4.6.1.2 Saudi Arabia: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.6.1.3 Saudi Arabia: Antibody Drug Conjugates Market, by Technology
    - 10.4.6.1.4 Saudi Arabia: Antibody Drug Conjugates Market, by Application
    - 10.4.6.1.5 Saudi Arabia: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.4.6.2 UAE
    - 10.4.6.2.1 Overview
    - 10.4.6.2.2 UAE: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.6.2.3 UAE: Antibody Drug Conjugates Market, by Technology
    - 10.4.6.2.4 UAE: Antibody Drug Conjugates Market, by Application
    - 10.4.6.2.5 UAE: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.4.6.3 South Africa
    - 10.4.6.3.1 Overview
    - 10.4.6.3.2 South Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.6.3.3 South Africa: Antibody Drug Conjugates Market, by Technology
    - 10.4.6.3.4 South Africa: Antibody Drug Conjugates Market, by Application
    - 10.4.6.3.5 South Africa: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.4.6.4 Rest of Middle East & Africa
    - 10.4.6.4.1 Overview
    - 10.4.6.4.2 Rest of Middle East & Africa: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.4.6.4.3 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Technology
    - 10.4.6.4.4 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Application
    - 10.4.6.4.5 Rest of Middle East & Africa: Antibody Drug Conjugates Market, by Distribution Channel
10.5 South & Central America Antibody Drug Conjugates Market, Revenue and Forecast To 2030
- 10.5.1 Overview
- 10.5.2 Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
- 10.5.3 South & Central America: Antibody Drug Conjugates Market, by Technology
- 10.5.4 South & Central America: Antibody Drug Conjugates Market, by Application
- 10.5.5 South & Central America: Antibody Drug Conjugates Market, by Distribution Channel
- 10.5.6 South & Central America: Antibody Drug Conjugates Market, by Country
  - 10.5.6.1 Brazil
    - 10.5.6.1.1 Overview
    - 10.5.6.1.2 Brazil: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.6.1.3 Brazil: Antibody Drug Conjugates Market, by Technology
    - 10.5.6.1.4 Brazil: Antibody Drug Conjugates Market, by Application
    - 10.5.6.1.5 Brazil: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.5.6.2 Argentina
    - 10.5.6.2.1 Overview
    - 10.5.6.2.2 Argentina: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.6.2.3 Argentina: Antibody Drug Conjugates Market, by Technology
    - 10.5.6.2.4 Argentina: Antibody Drug Conjugates Market, by Application
    - 10.5.6.2.5 Argentina: Antibody Drug Conjugates Market, by Distribution Channel
  - 10.5.6.3 Rest of South & Central America
    - 10.5.6.3.1 Overview
    - 10.5.6.3.2 Rest of South & Central America: Antibody Drug Conjugates Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.5.6.3.3 Rest of South & Central America: Antibody Drug Conjugates Market, by Technology
    - 10.5.6.3.4 Rest of South & Central America: Antibody Drug Conjugates Market, by Application
    - 10.5.6.3.5 Rest of South & Central America: Antibody Drug Conjugates Market, by Distribution Channel

11. Antibody Drug Conjugates Market-Industry Landscape

11.1 Overview
11.2 Organic Growth Strategies
- 11.2.1 Overview
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Companies' Manufacturing Capacities and Capabilities

12. Company Profiles

12.1 ADC Therapeutics SA
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Pfizer Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Hoffmann-La Roche Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 ImmunoGen, Inc.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 GSK Plc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Gilead Sciences Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 AstraZeneca Plc
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Astellas Pharma Inc
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
12.9 RemeGen Co Ltd
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
12.10 Takeda Pharmaceutical Co Ltd
- 12.10.1 Key Facts
- 12.10.2 Business Description
- 12.10.3 Products and Services
- 12.10.4 Financial Overview
- 12.10.5 SWOT Analysis
- 12.10.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms

02-2025-2992
(주말 및 공휴일 제외)

라이선스 / 가격

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다.

US $ 4,550

￦ 6,771,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,550

￦ 9,747,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,550

￦ 12,724,000

※ 부가세 별도